Until now, no specific drug to kill the virus that causes COVID-19 has received approval from the Food and Drug Association (FDA). However, the drugs that are often used are off-label antiviral drugs. The research design used is an umbrella review that identifies, assesses and interprets all findings on a systematic review and meta-analysis research topic. This umbrella review research involved 76 studies and 871,985 COVID-19 patients. Statins, colchicine, aspirin and siltuximab are associated with a reduced risk of mortality in COVID-19 patients, but siltuximab has the side effects of cytopenias, infections and hypersensitivity reactions. Remdesivir and umifenovir have the side effect of diarrhea, while ribavirin has the side effect of severe bradycardia in COVID-19 patients. Anakinra, oseltamivir, umifenovir, azithromycin, interferon beta and favipiravir are ineffective and have no significant benefit. Meanwhile, treating COVID-19 with traditional Chinese medicine (TCM) combined with conventional medicine has excellent results, efficacy, and safety effects. Only Jinhua qinggan granule (JHQG) has side effects in the form of mild diarrhea. Further research is needed regarding the concentration of TCM administered to COVID-19 patients, both children and adults.

COVID 19, COVID-19 Treatment, 2019-nCov

Biancolella M, Colona VL, Luzzatto L, Watt JL, Mattiuz G, Conticello SG, et al. COVID-19 annual update: a narrative review. Human genomics. 2023;17(1):68.

Parums DV. Editorial: A Rapid Global Increase in COVID-19 is Due to the Emergence of the EG.5 (Eris) Subvariant of Omicron SARS-CoV-2. Medical science monitor : international medical journal of experimental and clinical research. 2023;29:e942244.

Wadaa-Allah A, Emhamed MS, Sadeq MA, Ben Hadj Dahman N, Ullah I, Farrag NS, et al. Efficacy of the current investigational drugs for the treatment of COVID-19: a scoping review. Ann Med. 2021;53(1):318-34.

Stasi C, Fallani S, Voller F, Silvestri C. Treatment for COVID-19: An overview. Eur J Pharmacol. 2020;889:173644.

Juul S, Nielsen EE, Feinberg J, Siddiqui F, Jørgensen CK, Barot E, et al. Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). PLoS One. 2021;16(3):e0248132.

Kim MS, An MH, Kim WJ, Hwang TH. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. PLoS Med. 2020;17(12):e1003501.

Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. J Med Virol. 2020;92(6):556-63.

Şimşek Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci. 2020;50(Si-1):611-9.

Kumar Verma A, Kumar V, Singh S, Goswami BC, Camps I, Sekar A, et al. Repurposing potential of Ayurvedic medicinal plants derived active principles against SARS-CoV-2 associated target proteins revealed by molecular docking, molecular dynamics and MM-PBSA studies. Biomed Pharmacother. 2021;137:111356.

Zhuang J, Dai X, Wu Q, Cai H, Fu X, Zhang W, et al. A meta-analysis for Lianhua Qingwen on the treatment of Coronavirus disease 2019 (COVID-19). Complement Ther Med. 2021;60:102754.

Gajewski A, Kośmider A, Nowacka A, Puk O, Wiciński M. Potential of herbal products in prevention and treatment of COVID-19. Literature review. Biomed Pharmacother. 2021;143:112150.

Kollias A, Kyriakoulis KG, Kyriakoulis IG, Nitsotolis T, Poulakou G, Stergiou GS, et al. Statin use and mortality in COVID-19 patients: Updated systematic review and meta-analysis. Atherosclerosis. 2021;330:114-21.

Diaz-Arocutipa C, Melgar-Talavera B, Alvarado-Yarasca Á, Saravia-Bartra MM, Cazorla P, Belzusarri I, et al. Statins reduce mortality in patients with COVID-19: an updated meta-analysis of 147 824 patients. Int J Infect Dis. 2021;110:374-81.

Wu KS, Lin PC, Chen YS, Pan TC, Tang PL. The use of statins was associated with reduced COVID-19 mortality: a systematic review and meta-analysis. Ann Med. 2021;53(1):874-84.

Simmons B, Wentzel H, Mobarak S, Eslami G, Sadeghi A, Ali Asgari A, et al. Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis. J Antimicrob Chemother. 2021;76(2):286-91.

Nawangsih EN, Kusmala YY, Rakhmat, II, Handayani DR, Juliastuti H, Wibowo A, et al. Colchicine and mortality in patients with coronavirus disease 2019 (COVID-19) pneumonia: A systematic review, meta-analysis, and meta-regression. Int Immunopharmacol. 2021;96:107723.

Mikolajewska A, Fischer AL, Piechotta V, Mueller A, Metzendorf MI, Becker M, et al. Colchicine for the treatment of COVID-19. Cochrane Database Syst Rev. 2021;10(10):Cd015045.

Hariyanto TI, Halim DA, Jodhinata C, Yanto TA, Kurniawan A. Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Clin Exp Pharmacol Physiol. 2021;48(6):823-30.

Elshafei MN, El-Bardissy A, Khalil A, Danjuma M, Mubasher M, Abubeker IY, et al. Colchicine use might be associated with lower mortality in COVID-19 patients: A meta-analysis. Eur J Clin Invest. 2021;51(9):e13645.

Golpour M, Mousavi T, Alimohammadi M, Mosayebian A, Shiran M, Alizadeh Navaei R, et al. The effectiveness of Colchicine as an anti-inflammatory drug in the treatment of coronavirus disease 2019: Meta-analysis. Int J Immunopathol Pharmacol. 2021;35:20587384211031763.

Martha JW, Pranata R, Lim MA, Wibowo A, Akbar MR. Active prescription of low-dose aspirin during or prior to hospitalization and mortality in COVID-19: A systematic review and meta-analysis of adjusted effect estimates. Int J Infect Dis. 2021;108:6-12.

Srivastava R, Kumar A. Use of aspirin in reduction of mortality of COVID-19 patients: A meta-analysis. Int J Clin Pract. 2021;75(11):e14515.

Khan FA, Stewart I, Fabbri L, Moss S, Robinson K, Smyth AR, et al. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Thorax. 2021;76(9):907-19.

Pasin L, Cavalli G, Navalesi P, Sella N, Landoni G, Yavorovskiy AG, et al. Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies. Eur J Intern Med. 2021;86:34-40.

Perveen RA, Nasir M, Talha KA, Selina F, Islam MA. Systematic review on current antiviral therapy in COVID-19 pandemic. Med J Malaysia. 2020;75(6):710-6.

Amani B, Amani B, Zareei S, Zareei M. Efficacy and safety of arbidol (umifenovir) in patients with COVID-19: A systematic review and meta-analysis. Immun Inflamm Dis. 2021;9(4):1197-208.

Song Y, Zhang M, Yin L, Wang K, Zhou Y, Zhou M, et al. COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2). Int J Antimicrob Agents. 2020;56(2):106080.

Liu W, Zhou P, Chen K, Ye Z, Liu F, Li X, et al. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis. Cmaj. 2020;192(27):E734-e44.

Xiang HR, Cheng X, Li Y, Luo WW, Zhang QZ, Peng WX. Efficacy of IVIG (intravenous immunoglobulin) for corona virus disease 2019 (COVID-19): A meta-analysis. Int Immunopharmacol. 2021;96:107732.

Zhong H, Wang Y, Zhang ZL, Liu YX, Le KJ, Cui M, et al. Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis. Pharmacol Res. 2020;157:104872.

Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. Bmj. 2020;370:m2980.

Ghazy RM, Almaghraby A, Shaaban R, Kamal A, Beshir H, Moursi A, et al. A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment. Sci Rep. 2020;10(1):22139.

Nakhlband A, Fakhari A, Azizi H. Interferon-beta offers promising avenues to COVID-19 treatment: a systematic review and meta-analysis of clinical trial studies. Naunyn Schmiedebergs Arch Pharmacol. 2021;394(5):829-38.

Manabe T, Kambayashi D, Akatsu H, Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):489.

Özlüşen B, Kozan Ş, Akcan RE, Kalender M, Yaprak D, Peltek İ B, et al. Effectiveness of favipiravir in COVID-19: a live systematic review. Eur J Clin Microbiol Infect Dis. 2021;40(12):2575-83.

Hassanipour S, Arab-Zozani M, Amani B, Heidarzad F, Fathalipour M, Martinez-de-Hoyo R. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci Rep. 2021;11(1):11022.

Wang D, Li Z, Liu Y. An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics. J Infect Public Health. 2020;13(10):1405-14.

Tharmarajah E, Buazon A, Patel V, Hannah JR, Adas M, Allen VB, et al. IL-6 inhibition in the treatment of COVID-19: A meta-analysis and meta-regression. J Infect. 2021;82(5):178-85.

Alkofide H, Almohaizeie A, Almuhaini S, Alotaibi B, Alkharfy KM. Tocilizumab and Systemic Corticosteroids in the Management of Patients with COVID-19: A Systematic Review and Meta-Analysis. Int J Infect Dis. 2021;110:320-9.

Avni T, Leibovici L, Cohen I, Atamna A, Guz D, Paul M, et al. Tocilizumab in the treatment of COVID-19-a meta-analysis. Qjm. 2021;114(8):577-86.

Berardicurti O, Conforti A, Ruscitti P, Cipriani P, Giacomelli R. The wide spectrum of Kawasaki-like disease associated with SARS-CoV-2 infection. Expert Rev Clin Immunol. 2020;16(12):1205-15.

Chen CX, Hu F, Wei J, Yuan LT, Wen TM, Gale RP, et al. Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19). Leukemia. 2021;35(6):1661-70.

Kyriakopoulos C, Ntritsos G, Gogali A, Milionis H, Evangelou E, Kostikas K. Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis. Respirology. 2021;26(11):1027-40.

Lan SH, Lai CC, Huang HT, Chang SP, Lu LC, Hsueh PR. Tocilizumab for severe COVID-19: a systematic review and meta-analysis. Int J Antimicrob Agents. 2020;56(3):106103.

Lin WT, Hung SH, Lai CC, Wang CY, Chen CH. The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials. Int Immunopharmacol. 2021;96:107602.

Mahroum N, Watad A, Bridgewood C, Mansour M, Nasr A, Hussein A, et al. Systematic Review and Meta-Analysis of Tocilizumab Therapy versus Standard of Care in over 15,000 COVID-19 Pneumonia Patients during the First Eight Months of the Pandemic. Int J Environ Res Public Health. 2021;18(17).

Nugroho CW, Suryantoro SD, Yuliasih Y, Rosyid AN, Asmarawati TP, Andrianto L, et al. Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis. F1000Res. 2021;10:73.

Rezaei S, Fatemi B, Karimi Majd Z, Minaei H, Peikanpour M, Anjidani N, et al. Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis. Expert Rev Clin Immunol. 2021;17(5):499-511.

Rubio-Rivas M, Forero CG, Mora-Luján JM, Montero A, Formiga F, Homs NA, et al. Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis. Pharmacotherapy. 2021;41(11):884-906.

Sarfraz A, Sarfraz Z, Sarfraz M, Aftab H, Pervaiz Z. Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies. Turk J Med Sci. 2021;51(3):890-7.

Selvaraj V, Khan MS, Bavishi C, Dapaah-Afriyie K, Finn A, Lal A, et al. Tocilizumab in Hospitalized Patients with COVID-19: A Meta Analysis of Randomized Controlled Trials. Lung. 2021;199(3):239-48.

Snow TAC, Saleem N, Ambler G, Nastouli E, Singer M, Arulkumaran N. Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials. Intensive Care Med. 2021;47(6):641-52.

Solis-García Del Pozo J, Galindo MF, Nava E, Jordán J. A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients. Eur Rev Med Pharmacol Sci. 2020;24(13):7475-84.

Berardicurti O, Ruscitti P, Ursini F, D'Andrea S, Ciaffi J, Meliconi R, et al. Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis. Clin Exp Rheumatol. 2020;38(6):1247-54.

Chen MR, Kuo HC, Lee YJ, Chi H, Li SC, Lee HC, et al. Phenotype, Susceptibility, Autoimmunity, and Immunotherapy Between Kawasaki Disease and Coronavirus Disease-19 Associated Multisystem Inflammatory Syndrome in Children. Front Immunol. 2021;12:632890.

Joseph BA, Dibas M, Evanson KW, Paranjape G, Vegivinti CTR, Selvan PT, et al. Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review. Expert Rev Anti Infect Ther. 2021;19(6):679-87.

Fragkou PC, Belhadi D, Peiffer-Smadja N, Moschopoulos CD, Lescure FX, Janocha H, et al. Review of trials currently testing treatment and prevention of COVID-19. Clin Microbiol Infect. 2020;26(8):988-98.

Axfors C, Schmitt AM, Janiaud P, Van't Hooft J, Abd-Elsalam S, Abdo EF, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021;12(1):2349.

Wang Y, Lu C, Li H, Qi W, Ruan L, Bian Y, et al. Efficacy and safety assessment of severe COVID-19 patients with Chinese medicine: A retrospective case series study at early stage of the COVID-19 epidemic in Wuhan, China. J Ethnopharmacol. 2021;277:113888.

Vargas M, Servillo G, Einav S. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review. Eur Rev Med Pharmacol Sci. 2020;24(16):8592-605.

Song G, Qiao W, Wang X, Yu X. Association of Lung Ultrasound Score with Mortality and Severity of COVID-19: A Meta-Analysis and Trial Sequential Analysis. Int J Infect Dis. 2021;108:603-9.

Kaka AS, MacDonald R, Greer N, Vela K, Duan-Porter W, Obley A, et al. Major Update: Remdesivir for Adults With COVID-19 : A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points. Ann Intern Med. 2021;174(5):663-72.

Musa A, Pendi K, Hashemi A, Warbasse E, Kouyoumjian S, Yousif J, et al. Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature. West J Emerg Med. 2020;21(4):737-41.

Okoli GN, Rabbani R, Copstein L, Al-Juboori A, Askin N, Abou-Setta AM. Remdesivir for coronavirus disease 2019 (COVID-19): a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials. Infect Dis (Lond). 2021;53(9):691-9.

Rezagholizadeh A, Khiali S, Sarbakhsh P, Entezari-Maleki T. Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis. Eur J Pharmacol. 2021;897:173926.

Shrestha DB, Budhathoki P, Syed NI, Rawal E, Raut S, Khadka S. Remdesivir: A potential game-changer or just a myth? A systematic review and meta-analysis. Life Sci. 2021;264:118663.

Yokoyama Y, Briasoulis A, Takagi H, Kuno T. Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials. Virus Res. 2020;288:198137.

Singh S, Khera D, Chugh A, Khera PS, Chugh VK. Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis. BMJ Open. 2021;11(6):e048416.

Du X, Shi L, Cao W, Zuo B, Zhou A. Add-on effect of Chinese herbal medicine in the treatment of mild to moderate COVID-19: A systematic review and meta-analysis. PLoS One. 2021;16(8):e0256429.

Jin L, Xu Y, Yuan H. Effects of four types of integrated Chinese and Western medicines for the treatment of COVID-19 in China: a network meta-analysis. Rev Assoc Med Bras (1992). 2020;66(6):771-7.

Zhou H, Chen D, Zhang Y, Zhu Q, Yang Y, Liu Y, et al. Efficacy and safety of Xiyanping for COVID-2019: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2020;99(46):e22962.

Wang Y, Han L, Zhang W, Sun J. The curative effect of Reduning injection combined with Xuanfeibaidu formula on COVID-19: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2020;99(46):e22830.

Liang SB, Fang M, Liang CH, Lan HD, Shen C, Yan LJ, et al. Therapeutic effects and safety of oral Chinese patent medicine for COVID-19: A rapid systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2021;60:102744.

Sun CY, Sun YL, Li XM. The role of Chinese medicine in COVID-19 pneumonia: A systematic review and meta-analysis. Am J Emerg Med. 2020;38(10):2153-9.

Zhou LP, Wang J, Xie RH, Pakhale S, Krewski D, Cameron DW, et al. The Effects of Traditional Chinese Medicine as an Auxiliary Treatment for COVID-19: A Systematic Review and Meta-Analysis. J Altern Complement Med. 2021;27(3):225-37.

Vrachatis DA, Giannopoulos GV, Giotaki SG, Raisakis K, Kossyvakis C, Iliodromitis KE, et al. Impact of colchicine on mortality in patients with COVID-19: A meta-analysis. Hellenic J Cardiol. 2021;62(5):374-7.

Song LG, Xie QX, Lao HL, Lv ZY. Human coronaviruses and therapeutic drug discovery. Infect Dis Poverty. 2021;10(1):28.